Another possible case of PrEP 'breakthrough' infection reported
How much 'PrEP-resistant' HIV is out there?
Ibalizumab, active against highly resistant HIV, now approved in US
Efavirenz may undermine effectiveness of the vaginal ring contraceptive
Average time from HIV diagnosis to treatment fell to six days in 2016 in San Francisco
Biktarvy combo maintains viral suppression after switching therapy
Same-day treatment start improves retention in care and viral suppression in Lesotho
Twice-daily dolutegravir is safe and effective when used alongside TB treatment
Antiretroviral drug levels in hair strongly predict viral suppression
